Nonetheless, several Eph receptors — notably EphA2 — have been proposed as therapeutic targets in oncology due to their aberrant expression in many cancers, which has been correlated with invasive and metastatic disease (Liu et al., 2022; Pergaris et al., 2021). The gene discussed is EPHA2; the disease is cancer.